occurred in 11% of recently diagnosed patients. Table 2 Survey-Based Characteristics of Patients With MDS Lower-risk MDS was more common than higher-risk MDS among both recently diagnosed cases (68%–69% vs. 31%–32%, respectively) and
Search Results
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
Mikkael A. Sekeres
Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults
Kah Poh Loh, Vivian Lam, Katey Webber, Simran Padam, Mina S. Sedrak, Vivek Musinipally, Madison Grogan, Carolyn J. Presley, Janice Grandi, Chandrika Sanapala, Daniel A. Castillo, Grace DiGiovanni, Supriya G. Mohile, Louise C. Walter, and Melisa L. Wong
characteristics are associated with these changes can inform shared decision-making to individualize cancer care. Identifying which patients are at highest risk of functional decline is necessary to weigh the potential benefits and harms of treatment options, to
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
and the ICI therapy course and lead to morbidity and mortality. Given the limited data on IMM, we evaluated the clinical characteristics, disease course, treatment, and outcome of IMM in patients at a tertiary cancer center. Methods Study
Edmonton Symptom Assessment Scale and Clinical Characteristics Associated With Cannabinoid Use in Oncology Supportive Care Outpatients
Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan, and Diane Portman
characteristics among patients with positive versus negative test results. Patients and Methods Study Population A retrospective medical records review was performed to identify reported differences in symptom characteristics of cannabinoid users and nonusers
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials
Ramy Sedhom, Amanda L. Blackford, Arjun Gupta, Kelly Griffiths, Janet Heussner, and Michael A. Carducci
solid cancer and enrollment in a phase I intervention trial. The primary objective of this study was to identify patient and treatment characteristics associated with a short hospice LOS (≤3 days). Data Collection Patient demographics and EOL
Lung Cancer in Nonelderly Patients: Facility and Patient Characteristics Associated With Not Receiving Treatment
Elizabeth A. Nardi, Can-Lan Sun, Francisco Robert, and Julie A. Wolfson
(“treatment”). Sociodemographic Characteristics The following sociodemographic variables were included in multivariable analyses: (1) age (continuous variable); (2) year of diagnosis (11 categories); (3) race/ethnicity (non-Hispanic white [NHW], black
EPR19-072: Breast Cancer Laterality and Immunohistochemical Characteristics
Tarek Safi, Pascale Salameh, Lea Aoude, Mirna Waked, FCCP, and Bassim Kobrossy
looking at differences in immunohistochemical characteristics between left and right sided breast cancer. This study aims to assess the incidence and age distribution as well as the following immunohistochemical characteristics: estrogen receptor (ER
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States
Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna
review of the EHR, Social Security Death Index, and review of obituaries. 19 Statistical Analysis Baseline characteristics of patients who received TAS-102 alone or prior to receiving regorafenib (TAS-102 group) versus those who received
Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States
Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu
-beam RT to the brain who met the inclusion criteria. Statistical Methodology Patient-level characteristics included age, year of diagnosis, sex, malignancy type, Charlson-Deyo comorbidity score (CDS), race/ethnicity, insurance status, distance from
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Mohanlal, and Gary H. Lyman
our analysis. Rates of PP G-CSF use, defined as ≥1 claim for a G-CSF on or up to 3 days after the date of chemotherapy initiation (index date), were assessed overall and by regimen. Baseline characteristics were evaluated during the 6-month period
